## Evaluation of Hydrogen Bonding Complementarity between a Secondary Sulfonamide and an α-Amino Acid Residue

Joseph M. Langenhan,<sup>†</sup> John D. Fisk,<sup>§</sup> and Samuel H. Gellman<sup>\*,†,§</sup>

Department of Chemistry and Graduate Program in Biophysics, University of Wisconsin, Madison, Wisconsin 53706

gellman@chem.wisc.edu

Received June 6, 2001

## ABSTRACT



We report an initial step toward the development of sulfonamide-based complements for extended peptide strands. A molecule containing one secondary sulfonamide unit and one valine residue linked by a turn-forming segment was found by IR and NMR to exhibit a doubly hydrogenbonded folding pattern in chloroform.

Non-peptidic molecules that display hydrogen bonding complementarity to peptides in the extended (" $\beta$ -strand") conformation<sup>1</sup> are of interest for biomedical applications. Such molecules might disrupt the formation of amyloid fibrils,<sup>2</sup>  $\beta$ -sheet type aggregates that are associated with a variety of diseases.<sup>3</sup> Non-peptidic  $\beta$ -strand complements could also provide a basis for disrupting protein—protein interactions that depend on the recognition of peptide segments in an extended conformation.<sup>4</sup> Here we explore the prospect that secondary sulfonamide groups might be employed to generate hydrogen bonding complements to peptide  $\beta$ -strands.

Secondary sulfonamides differ conformationally from secondary carboxamides in two important ways: (i) the barrier to rotation about the S-N bond is much smaller than

the barrier to rotation about the C–N bond,<sup>5</sup> and (ii) one of the H–N–S=O torsion angles is often near  $0^{\circ,5}$  while the H–N–C=O torsion angle is usually around 180°. These

ORGANIC LETTERS

2001 Vol. 3, No. 16

2559 - 2562

Department of Chemistry.

<sup>§</sup> Graduate Program in Biophysics.

Nowick, J. Š.; Chung, D. M.; Maitra, K.; Maitra, S.; Stigers, K. D.;
Sun, Y. J. Am. Chem. Soc. 2000, 122, 7654. Nowick, J. S.; Tsai, J. H.;
Bui, Q.-C. D.; Maitra, S. J. Am. Chem. Soc. 1999, 121, 8409. Nowick, J.
S.; Pairish, M.; Lee, I. Q.; Holmes, D. L.; Ziller, J. W. J. Am. Chem. Soc. 1997, 119, 5413. Smith, E. M.; Holmes, D. L.; Shaka, A. J.; Nowick, J. S.
J. Org. Chem. 1997, 62, 7906. Kemp, D. S.; Bowen, B. R.; Muendel, C. C.
J. Org. Chem. 1990, 55, 4650. Schrader, T. H.; Kirsten, C. N. J. Am. Chem. Soc. 1997, 119, 12061.

<sup>(2)</sup> Reports of molecules that disrupt amyloid aggregation: Pallitto, M. M.; Ghanta, J.; Heinzelman, P.; Kiessling, L. L.; Murphy, R. M. Biochemistry 1999, 38, 3570. Ghanta, J.; Shen, C.-L.; Kiessling, L. L.; Murphy, R. M. J. Biol. Chem. 1996, 271, 29525. Tjernberg, L. S.; Lillichook, C.; Callaway, D. J. E.; Naslund, J.; Hahne, S.; Thyberg, J.; Terenius, L.; Nordstedt, C. J. Biol. Chem. 1997, 272, 12601. Tjernberg, L. O.; Naslund, J.; Lindqvist, F.; Johansson, J.; Karlstrom, A. R.; Thyberg, J.; Terenius, L.; Nordstedt, C. J. Biol. Chem. 1996, 271, 8545. Soto, C.; Kascsak, R. J.; Saborio, G. P.; Aucutrier, P.; Wisniewski, T.; Prelli, F.; Kascsak, R. J.; Saborio, G. P.; Aucutrier, P.; Wisniewski, T.; Prelli, F.; Kascsak, R.; Mendez, E.; Harris, D. A.; Ironside, J.; Curran, G.; Kumar, A.; Frangione, B. Lancet 2000, 355, 192. Poduslo, J.; Curran, G.; Kumar, A.; Frangione, B.; Soto, C. J. Neurobiol. 1999, 31, 371. Soto, C.; Sigurdsson, E. M.; Morelli, L.; Kumar, R. A.; Castano, E. M.; Frangione, B. Nat. Med. 1998, 4, 822. Soto, C.; Kindy, M. S.; Baumann, M.; Frangione, B. Biochem. Biophys. Res. Commun. 1996, 273, 13203.

<sup>(3)</sup> An alternative approach toward addressing human amyloid disorders involves stabilization of native protein conformation: Klabunde, T.; Petrassi, H. M.; Oza, V. B.; Raman, P.; Kelly, J. W.; Sacchettini, J. C. *Nat. Struct. Biol.* **2000**, *7*, 312. Miroy, G. J.; Lai, Z.; Lashuel, H. A.; Peterson, S. A.; Strang, C.; Kelly, J. W. *Proc. Natl. Acad. Sci. U.S.A.* **1996**, *93*, 15051.

<sup>(4)</sup> The PDZ domain recognizes extended strands: Harrison, S. *Cell* **1996**, 86, 341. Doyle, D.; Lee, A.; Lewis, J.; Kim, E.; Sheng, M.; MacKinnon, R. *Cell* **1996**, 85, 1067. Cabral, J.; Petosa, C.; Sutcliffe, M.; Raza, S.; Byron, O.; Poy, F.; Marfatia, S.; Chishti, A.; LIddington, R. *Nature* **1996**, *382*, 649.

conformational disparities lead to a difference in hydrogen bonding behavior. The N-H and C=O of a secondary carboxamide cannot interact simultaneously with a closely spaced acceptor/donor pair. In contrast, the N-H and S=O of a secondary sulfonamide can achieve this type of twopoint interaction. These structural considerations led us to contemplate the hydrogen bonding motif shown in Figure 1, in which a secondary sulfonamide interacts with both the



Figure 1. The two-point hydrogen-bonded interaction between a secondary sulfonamide group and the C=O and N-H of a single peptide residue.

C=O and N-H of a single  $\alpha$ -amino acid residue. A general strategy for designing sulfonamide-based  $\beta$ -strand mimics could be achieved if this two-point interaction were favorable, and if we could identify amino sulfonic acid residues that allow complementary hydrogen bonding between an oligo-sulfonamide<sup>6,7</sup> and an extended peptide strand.

Here we report our initial step toward the development of sulfonamide strand mimics, using a hairpin folding motif to evaluate hydrogen bonding complementarity between a single secondary sulfonamide group and an  $\alpha$ -amino acid residue in an organic solvent. Molecular hairpins have been previously employed to evaluate hydrogen bonding complementarity in the context of amide, vinylogous amide, urea, and hydrazine functionalities.<sup>1,8</sup> To achieve the desired two-point hydrogen bond between the peptide and sulfonamide groups (Figure 1), we required a turn unit containing two amino termini. The prolyl-(1,1-dimethyl)-1,2-diaminoethyl turn previously described for linking two peptide strands via their C-termini<sup>9</sup> appeared suitable. Thus, molecule **1**, containing one secondary sulfonamide unit and one valine residue to

(7) Peptides that bind to oligosulfonamides have been identified previously through screening processes: Gennari, C.; Nestler, H.; Salom, B.; Still, W. Angew. Chem., Int. Ed. Engl. 1995, 34, 1765. Brouwer, A.; Linden, H. v. d.; Liskamp, R. J. Org. Chem. 2000, 65, 1750. Lowik, D.; Weingarten, M.; Broekema, M.; Brouwer, A.; Still, W.; Liskamp, R. Angew. Chem., Int. Ed. 1998, 37, 1846. Lowik, D.; Mulders, S.; Cheng, Y.; Shao, Y.; Liskamp, R. Tetrahedron Lett. 1996, 37, 8253.

(8) Nowick, J. S. Acc. Chem. Res. **1999**, 32, 287–296. Hagihara, M.; Anthony, N. J.; Stout, T. J.; Clardy, J.; Schreiber, S. L. J. Am. Chem. Soc. **1992**, 114, 6568. which the sulfonamide can form hydrogen bonds, was synthesized and examined for intramolecular hydrogen bonding using IR and NMR methods.<sup>10</sup>

We compared the N–H stretch region IR spectrum of 1 to the IR spectrum of non hydrogen bonded reference compounds 2 and 3 (Figure 2). The spectra were recorded



Figure 2. IR spectra of 1-3 at 1 mM in CDCl<sub>3</sub>.

at 1 mM in CDCl<sub>3</sub>, a concentration at which no aggregation of 1 occurs (vide infra). On the IR time scale hydrogen bonding equilibria are slow, and discrete bands representing hydrogen bonded and non hydrogen bonded states can be observed for a given NH group. The spectrum of reference 2 contains one NH absorbance, at 3428 cm<sup>-1</sup>. This signal has been attributed to an NH involved in a "C<sub>5</sub> interaction," a weak intraresidue five-membered ring N-H···O=C interaction.<sup>11</sup> Two bands are observed in the spectrum of reference **3**, a non hydrogen bonded carboxamide NH



absorbance (3438 cm<sup>-1</sup>) and an absorbance at 3389 cm<sup>-1</sup>, which corresponds to the reported range for non hydrogen bonded sulfonamide NH stretch.<sup>6a,12</sup> These reference compound data allowed us to interpret the more complex

<sup>(5)</sup> Radkiewicz, J. L.; McAllister, M. A.; Goldstein, E.; Houk, K. N. J. Org. Chem. **1998**, 63, 1419. Heyd, J.; Thiel, W.; Weber, W. Theochem **1997**, 391, 125.

<sup>(6)</sup> Secondary oligosulfonamides: (a) Gennari, C.; Salom, B.; Potenza, D.; Longari, C.; Fioravanzo, E.; Carugo, O.; Sardone, N. Chem. Eur. J. 1996, 3, 644. (b) Gude, M.; Piarulli, U.; Potenza, D.; Salom, B.; Gennari, C. Tetrahedron Lett. 1996, 37, 8589. (c) Gennari, C.; Nestler, H.; Salom, B.; Still, W. Angew. Chem., Int. Ed. Engl. 1995, 34, 1763. (d) Gennari, C.; Salom, B.; Potenza, D.; Williams, A. Angew. Chem., Int. Ed. Engl. 1994, 33, 2020. (e) Monnee, M.; Marijne, M.; Brouwer, A.; Liskamp, R. Tetrahedron Lett. 2000, 41, 7991. (f) Moree, W. J.; Marel, G. A. v. d.; Liskamp, R. J. J. Org. Chem 1995, 60, 5157.

spectrum of **1**. We assign the absorbance at  $3424 \text{ cm}^{-1}$  to a non hydrogen bonded carboxamide NH stretch. The broader band with a maximum at  $3366 \text{ cm}^{-1}$  can be attributed to a hydrogen bonded carboxamide NH stretch.<sup>13</sup> A discrete absorbance corresponding to a non hydrogen bonded sulfonamide NH ( $3389 \text{ cm}^{-1}$  in reference **3**) is not observed in the IR spectrum of **1**; however, a small absorbance at this position could be obscured by the two carboxamide NH signals. The broad band at  $3186 \text{ cm}^{-1}$  is assigned to a hydrogen bonded sulfonamide NH<sup>6a,12</sup> (a hydrogen bonded secondary carboxamide NH is never observed below 3250cm<sup>-1</sup>).<sup>13</sup> These results are consistent with the desired doubly hydrogen bonded conformation of **1**.

Amide chemical shift ( $\delta$ NH) values in a nonpolar solvent such as CDCl<sub>3</sub> are sensitive to the amide group's involvement in hydrogen bonds.<sup>13</sup> A hydrogen bonded NH group exhibits a downfield chemical shift relative to a non hydrogen bonded amide. Equilibration between hydrogen bonded and non hydrogen bonded states is usually fast on the NMR time scale; thus, each  $\delta$ NH represents a population-weighted average. Because of the sensitivity of  $\delta$ NH to hydrogen bonding,  $\delta$ NH values can provide insight on intramolecular hydrogen bonding patterns. For this type of analysis, it is important that hydrogen bond-mediated intermolecular associations not contribute to  $\delta$ NH. A study of  $\delta$ NH versus concentration revealed that no aggregation of 1 occurs at  $\leq 10$  mM (Figure 3). Thus all further experiments were performed at  $\leq 10$  mM.



Figure 3. Amide proton NMR chemical shift of 1 at room temperature, as a function of the logarithm of concentration, in  $CDCl_3$ .

Table 1 contains  $\delta$ NH values measured at 24 °C for 1–3 in CDCl<sub>3</sub> (1 mM). Only one set of <sup>1</sup>H resonances was observed for 1, suggesting the presence of only one amide

molecule	$\delta$ NH-1	δNH-2	$\delta$ NH-3
1	6.47	5.59	5.94
2	6.17		
3		5.42	5.24

rotamer about the proline/valine bond. Values of  $\delta$ NH for 2 and 3 are references for the non hydrogen bonded states of NH-1, NH-2, and NH-3. These data provide further evidence that the desired doubly hydrogen bonded conformation of 1 is populated in CDCl<sub>3</sub>. The sulfonamide  $\delta$ NH of 1 ( $\delta$ NH-3) is 0.70 ppm downfield of the sulfonamide  $\delta$ NH in reference 3, indicating significant involvement in hydrogen bonding. The value  $\delta NH$  of **1** ( $\delta NH$ -1) is shifted downfield relative to the  $\delta$ NH of reference 2, albeit to a lesser extent (0.30 ppm). Because the sulfonamide group is a weak hydrogen bond acceptor,<sup>6a,12</sup> only a small shift in  $\delta$ NH is expected for a carboxamide proton hydrogen bonded to a sulfonamide oxygen. The amide contained within the turn segment ( $\delta$ NH-2) exhibits only a modest downfield shift relative to the analogous amide in reference 3, suggesting that there is little or no intramolecular hydrogen bonding to NH-2 in 1. These observations indicate that the doubly hydrogen bonded conformation of **1** is populated to a significant extent in CDCl<sub>3</sub>.

NOESY<sup>14</sup> data obtained for **1** in CDCl<sub>3</sub> (10 mM) provide further support for these conclusions. First, strong NOEs between a proline  $\delta$  proton and both the valine  $\alpha$  proton and the valine  $\gamma$  protons were observed (Figure 4). These



Figure 4. Selected NOEs for 1 in CDCl<sub>3</sub> (10 mM).

NOEs define the proline/valine rotamer as Z (as shown in Figure 4). In addition to the expected sequential NOEs (not shown), **1** displayed an interstrand NOE between the sulfonamide NH and the valine NH. The presence of this NOE provides strong evidence that a hairpin-like conformation is significantly populated in CDCl<sub>3</sub>.

To the best of our knowledge, **1** is the first molecule for which a double hydrogen bonding pattern of the type shown in Figure 1 has been characterized. Preliminary results suggest that the prolyl-(1,1-dimethyl)-1,2-diaminoethyl turn unit is too short to allow formation of hairpins containing extended strands. Currents efforts involve the identification

<sup>(9)</sup> Fisk, J.; Powell, D.; Gellman, S. J. Am. Chem. Soc. 2000, 122, 5443. (10) For other hairpin-like structures containing sulfonamides, see ref 6a.

<sup>(11)</sup> Maxfield, F.; Leach, S.; Stimson, E.; Powers, S.; Scheraga, H. *Biopolymers* **1979**, *18*, 2507 and references therein.

<sup>(12)</sup> Gennari, C.; Gude, M.; Potenza, D.; Piarulli, U. Chem. Eur. J. 1998, 4, 1924.

<sup>(13)</sup> For leading references, see: Gardner, R.; Liang, G.-B.; Gellman, S. J. Am. Chem. Soc. **1999**, *121*, 1806. Dado, G.; Gellman, S. J. Am. Chem. Soc. **1993**, *115*, 4228. Gellman, S.; Dado, G.; Liang, G.-B.; Adams, B. J. Am. Chem. Soc. **1991**, *113*, 1164.

<sup>(14)</sup> Macura, S.; Ernst, R. R. Mol. Phys. 1980, 41, 95.

of new linkers. The data reported here are important because they demonstrate that the secondary sulfonamide unit represents a one-sided hydrogen bond complement to an  $\alpha$ -amino acid residue in the  $\beta$ -strand conformation.

Acknowledgment. This research was supported by the NIH (GM61238). J.M.L. was supported by a NSF Predoc-

toral Fellowship; J.D.F. was funded in part by a Molecular Biophysics Training Grant from NIGMS. NMR equipment was purchased in part with funds from the NSF (CHE-9629688) and the NIH (1 S10 RR0 8389-01).

OL016237X